Literature DB >> 22421462

Antibiotic-loaded polymethylmethacrylate beads for the treatment of extracavitary vascular surgical site infections.

Patrick A Stone1, Albeir Y Mousa, Stephen M Hass, D Daniel Dearing, James R Campbell, Ashley Parker, Stephanie Thompson, Ali F AbuRahma.   

Abstract

OBJECTIVE: This study assessed the efficacy of antibiotic-loaded polymethylmethacrylate (PMMA) beads in the treatment of lower extremity vascular surgical site infections (VSSIs).
METHODS: This was a retrospective review of all patients with a VSSI of a lower extremity bypass treated with antibiotic-loaded PMMA beads and culture-specific antibiotics during a 4.5-year period. Data collected included patient demographics, comorbidities, site of initial graft infection, symptoms and signs at presentation, initial and additional surgical debridement, wound culture results, type of antibiotic beads implanted, and graft treatment strategy, comprising conduit preservation or in situ replacement, with associated soft tissue management by muscle flap or vacuum-assisted closure. Primary outcome measures included death, recurrent infection, and limb salvage.
RESULTS: Forty patients developed 42 extracavitary lower extremity VSSIs (bilateral groin infections in two). Patients were treated according to our treatment algorithm with antibiotic-impregnated PMMA beads. Previous reconstructions included nine aortofemoral bypasses (groin infection only), 20 infrainguinal bypasses, five extra-anatomic bypasses, five femoral interpositions, two combined inflow-outflow bypass procedures, and one patch angioplasty with VSSI. Cultures isolated 59 pathogens (39 gram-positive, 18 gram-negative, 2 Candida spp). Methicillin-resistant Staphylococcus aureus was cultured from 10 VSSs (23.8%) overall and from 27.7% of those patients with attempted graft preservation or in situ reconstructions. Two patients (4.8%) had no growth despite clinical signs of infection. Repeat VSS exploration and culture results led to an average of 1.4 bead replacements before definitive treatment. Final treatment strategy included graft preservation of patent bypasses in 28, partial graft excision with in situ replacement in eight, graft removal only with residual graft remaining at implant site (ie, incorporated anastomotic conduit, 11.9%) in five, and extra-anatomic reconstruction in one. Sartorius muscle flap was performed in 14 groin infections (37.8%). The 30-day mortality was 0%, and limb loss was 7.1% (n = 3). At the median follow-up of 17 months, the limb loss was 21.4% and the recurrent infection rate was 19.4% (seven of 36) in those with attempted graft preservation or in situ replacement.
CONCLUSIONS: Antibiotic-loaded PMMA beads may serve as an adjunct in the management of VSSIs and may also expand treatment options for graft preservation or in situ reconstruction, with expected recurrent infection rate approaching 20%. Further experience with this adjunct may help elucidate its role in the management of this complicated problem, including the need for bead exchanges, until perigraft cultures are free of microbes.
Copyright © 2012 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22421462     DOI: 10.1016/j.jvs.2011.12.037

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  10 in total

Review 1.  Antibiotic-laden PMMA bead chains for the prevention of infection in compound fractures: current state of the art.

Authors:  David Seligson; Stephen Berling
Journal:  Eur J Orthop Surg Traumatol       Date:  2015-06-09

2.  Treatment of Infected Cardiac Implantable Electronic Devices.

Authors:  Abdulla Fakhro; Faryan Jalalabadi; Rodger H Brown; Shayan A Izaddoost
Journal:  Semin Plast Surg       Date:  2016-05       Impact factor: 2.314

3.  Salvage of Infected Prosthetic Breast Reconstructions.

Authors:  Amy S Xue; Katarzyna E Kania; Rodger H Brown; Jamal M Bullocks; Larry H Hollier; Shayan A Izaddoost
Journal:  Semin Plast Surg       Date:  2016-05       Impact factor: 2.314

Review 4.  Multidisciplinary Treatment Approach for Prosthetic Vascular Graft Infection in the Thoracic Aortic Area.

Authors:  Takeshiro Fujii; Yoshinori Watanabe
Journal:  Ann Thorac Cardiovasc Surg       Date:  2015-09-08       Impact factor: 1.520

5.  Bio-absorbable antibiotic impregnated beads for the treatment of prosthetic vascular graft infections.

Authors:  Elizabeth A Genovese; Efthymios D Avgerinos; Donald T Baril; Michel S Makaroun; Rabih A Chaer
Journal:  Vascular       Date:  2016-02-18       Impact factor: 1.285

6.  Prospective randomized double-blinded trial comparing 2 anti-MRSA agents with supplemental coverage of cefazolin before lower extremity revascularization.

Authors:  Patrick A Stone; Ali F AbuRahma; James R Campbell; Stephen M Hass; Albeir Y Mousa; Aravinda Nanjundappa; Mohit Srivastiva; Asmita Modak; Mary Emmett
Journal:  Ann Surg       Date:  2015-09       Impact factor: 12.969

7.  Noninvasive thrombectomy of graft by nano-magnetic ablating particles.

Authors:  Abbas Moghanizadeh; Fakhreddin Ashrafizadeh; Jaleh Varshosaz; Mahshid Kharaziha; Antoine Ferreira
Journal:  Sci Rep       Date:  2021-03-26       Impact factor: 4.996

8.  Sustained release of vancomycin from novel biodegradable nanofiber-loaded vascular prosthetic grafts: in vitro and in vivo study.

Authors:  Kuo-Sheng Liu; Cheng-Hung Lee; Yi-Chuan Wang; Shih-Jung Liu
Journal:  Int J Nanomedicine       Date:  2015-01-29

9.  Diagnosis and Treatment of Vascular Surgery Related Infection.

Authors:  Yong-Gan Zhang; Xue-Li Guo; Yan Song; Chao-Feng Miao; Chuang Zhang; Ning-Heng Chen
Journal:  Open Biomed Eng J       Date:  2015-09-17

10.  Effectiveness and Safety of Biodegradable Calcium Sulfate Antibiotic Beads as Adjuvant Therapy in Vascular Graft Infections.

Authors:  James B Doub; Jacqueline T Bork; Emily Heil; Kristen Stafford; Mary Banoub; John K Karwowski; Shahab Toursavadkohi
Journal:  Open Forum Infect Dis       Date:  2021-01-04       Impact factor: 3.835

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.